Wednesday, Jul 23rd

Last update09:43:47 AM GMT






You are here: BioMedTech


Vectura $10m inhaler windfall


Chris-BlackwellCambridge drug delivery business Vectura is set to collect a $10 million windfall from Novartis and earn subsequent royalty streams following a key approval for pioneering inhaler technology.

MedImmune-AZ-Roche form personalised medicines axis

Photograph courtesy: MedimmuneAstraZeneca has agreed a collaboration with Roche Diagnostics to develop companion diagnostics for selected products in development at AZ and MedImmune, which has a major and growing operation in the Cambridge UK technology cluster.

Vectura lands £2.5m Japan windfall

Dr Chris Blackwell, Vectura’s chief executive The Japanese government has handed a key approval to capsules for an inhaler device based on technology from Cambridge-based Vectura – handing the UK company a £2.5m milestone payment from partner Novartis.

BioFocus expands in Cambridge

Martin Sylvester of Churchmanor Estates, joint venture partners at Chesterford Research Park, with Chris Newton from BioFocusDrug discovery company BioFocus has expanded in Cambridge after closing its high throughput screening centre in Switzerland and rationalising the work of the two centres within the UK’s leading technology cluster.

Lightning strikes for Innova in Canada

At the core of Innova’s business are the Lightning-Link and InnovaCoat™ technologiesTechnology from Innova Biosciences in Cambridge UK is being harnessed by Canadian company StressMarq Biosciences to advance potential treatments for diseases such as cancer and diabetes.

Personalised cancer treatment breakthrough

Clearbridge BioMedics is a spin-off from the National University of SingaporeCambridge technology is at the heart of a new diagnostic device that can detect tumour cells from a simple blood sample – opening up the route to new personalised cancer treatments.

Cambridge misses out on US medical mission

Shamus HusheerBritain’s 20 hottest medical technology startups were unveiled by the UK government today for a mission to the US but not one business from Cambridge – Europe’s leading BioMedTech cluster – makes the plane.

Sphere Medical first half losses doubled

Sphere Medical CEO Stuart HendrySphere Medical, the Cambridge UK diagnostic device business, saw its first half losses double to £4.2 million after generating zero revenues in the six months to June 30.

Page 52 of 121